EC Number |
Expression |
Reference |
---|
2.1.1.1 | down |
exposure of BEAS-2B cells to induces NNMT repression at both the protein and mRNA levels |
756419 |
2.1.1.1 | down |
exposure to nickel induces NNMT repression at both the protein and mRNA levels |
756419 |
2.1.1.1 | more |
hepatic expression of Nnmt is highly variable and correlates with multiple metabolic parameters in mice |
-, 734757 |
2.1.1.1 | up |
expression is significantly elevated in a number of cancers, expression is significantly increased in the brains of patients who have died of Parkinsons disease |
718784 |
2.1.1.1 | up |
expression is significantly elevated in the diaphragm and quadriceps muscles of patients with chronic obstructive pulmonary disease. The relative induction of expression is greater in the quadriceps muscle (10-fold) than it is in the diaphragm(2-fold). Expression correlates negatively with these verity of chronic obstructive pulmonary disease and limb muscle wasting. Expression in skeletal myoblasts is significantly induced by IL-6, transforming growth factor beta, and tumor necrosis factor-alpha. Overexpression in myoblasts triggers a significant increase in proliferation and migration, but has no influence on cell death |
718554 |
2.1.1.1 | up |
expression is upregulated in the cutaneous squamous cell carcinoma SCC-12 cell line |
757884 |
2.1.1.1 | up |
gain-of-function non-coding micro-RNA-1291 miR-1291-altered PANC-1 cell function is associated with the increase in N-methylnicotinamide level and NNMT expression |
733614 |
2.1.1.1 | up |
highly upregulated inclear cell renal carcinoma cell |
719232 |
2.1.1.1 | up |
patients with manifest type 2 diabetes have an approximately twofold higher NNMTexpression both in omental and subcutaneous white adipose tissue compared with controls |
756556 |
2.1.1.1 | up |
progression of vascular inflammation and atherosclerosis is associated with the upregulation of hepatic NNMT activity and subsequent increase in endogenous 1-methylnicotinamide plasma levels |
-, 706094 |